Article
Vitamin D deficiency and associated factors in hemodialysis patients.
Centre de Rein Artificiel, Tassin la Demi-Lune, France.
Journal of Renal Nutrition (impact factor:
1.57).
10/2008;
18(5):395-9.
DOI:10.1053/j.jrn.2008.04.003
pp.395-9
Source: PubMed
-
Citations (0)
- Cited In (4)
-
Article: Vitamin D status in dark-skinned patients undergoing hemodialysis in a continually sunny country.
[show abstract] [hide abstract]
ABSTRACT: Background: Vitamin D (vitD) insufficiency is common in end-stage renal disease. Seasonal and ethnic differences in vitD status have been reported previously. We hypothesized that vitD status in Afro-Caribbean patients on hemodialysis (HD) living in a country with a constant sunny climate would be better than that in African-American HD patients living in countries with a winter season. Method: A cross-sectional study was conducted in152 Afro-Caribbean HD patients in a dialysis center located in Guadeloupe. We evaluated the prevalence of vitD insufficiency, defined as serum 25-hydroxyvitamin D (25(OH)D) levels below 30 ng/mL, compared with those results previously reported in African-American HD patients (88%). Results: Prevalence of vitD insufficiency was 60% and thus lower than that in the African-American patients considered as the reference population (p<0.001). In our diabetic patients, this prevalence was 72.4%. Globally, 9.2% of patients had 25(OH)D below 15 ng/mL. Alfacalcidol therapy was prescribed in 29%. Mean 25(OH)D levels were higher in treated than in untreated patients (32 vs. 27 ng/mL; p=0.009). Patients with vitD insufficiency had dyslipidemia and diabetes more frequently. No significant differences were found between patients with and without vitD insufficiency for serum calcium, phosphorus and parathyroid hormone (PTH). In untreated patients, no significant correlation was found between 25(OH)D and PTH levels. Conclusion: Prevalence of vitD insufficiency in Afro-Caribbean HD patients was lower than that previously reported in African Americans undergoing HD in the United States. This finding may be due to the constantly sunny weather with a high intensity of UVB radiation in Guadeloupe.Journal of nephrology 01/2012; · 1.65 Impact Factor -
Article: Forging forward with 10 burning questions on FGF23 in kidney disease.
[show abstract] [hide abstract]
ABSTRACT: The discovery of fibroblast growth factor 23 (FGF23) as the causal factor in the pathogenesis of rare forms of hypophosphatemic rickets is rapidly reshaping our understanding of disordered mineral metabolism in chronic kidney disease (CKD). Excessive production of FGF23 by osteocytes is an appropriate compensation to help maintain normal phosphorus metabolism in these patients. Beginning in early CKD, progressive increases in levels of FGF23 enhance phosphaturia on a per-nephron basis and inhibit calcitriol production, thereby contributing centrally to the predominant phosphorus phenotype of predialysis kidney disease: normal serum phosphate, increased fractional excretion of phosphate, and calcitriol deficiency. A proliferation of studies linking phosphorus and now FGF23 excess to adverse renal and cardiovascular outcomes in patients with CKD is setting the stage for novel clinical trials that could ultimately bring FGF23 testing into the clinic. Ten burning questions must be addressed to galvanize FGF23 research further in CKD.Journal of the American Society of Nephrology 09/2010; 21(9):1427-35. · 9.66 Impact Factor -
Article: Diagnostic Workup for Disorders of Bone and Mineral Metabolism in Patients with Chronic Kidney Disease in the Era of KDIGO Guidelines.
[show abstract] [hide abstract]
ABSTRACT: KDIGO (KIDNEY DISEASE: Improving Global Outcomes) is an international nonprofit organization devoted to "improve the care and outcomes of kidney disease patients worldwide through promoting coordination, collaboration, and integration of initiatives to develop and implement clinical practice guidelines." The mineral and bone disorder (MBD) in patients with chronic kidney disease (CKD) has been the first area of interest of KDIGO international initiative. KDIGO guidelines on CKD-MBD were published in 2009 with the intent to modify the previous KDOQI guidelines that had failed to consistently change the global outcome of CKD patients. After the publication of KDOQI guidelines for bone metabolism and disease in 2003, a large number of observational data emerged in literature linking disordered mineral metabolism with adverse clinical outcomes. Notwithstanding this large body of observational data, a paucity of evidence from high-quality clinical trials was available for the development of KDIGO guidelines. Herein, a summary will be provided of the most important findings of KDIGO guidelines regarding the diagnostic workup and clinical monitoring of CKD-MBD patients.International journal of nephrology. 01/2011; 2011:958798.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
1.5 mmol/L calcium dialysate
Calcidiol deficiency
chronic kidney disease
extrarenal calcitriol production
group 1 patients
group 2
group 3
Group 3 patients
hemodialysis patients
higher intact parathyroid hormone level
hip bone mineral density
lower dialysis vintage
potential direct action
prevalent hemodialysis patients
Quality Initiative guidelines
radiologic vascular calcification score
shorter dialysis duration
standard phosphate binder
sufficient vitamin D serum level
Vitamin D deficiency